1675-02-1

Erythromycin C is an intermediate in the biosynthesis of erythromycin . It is also a potential impurity found in commercial preparations of erythromycin. Erythromycin C is half as active or less than erythromycin A or B against most Gram-positive and Gram-negative bacteria tested.

Erythromycin (E649950) impurity. A related substance in Erythromycin drug.

Erythromycin C (3’’-O-demethylerythromycin A) is a minor co-metabolite of erythromycin produced by Saccharopolyspora erythreae. Erythromycin C exhibits a narrower spectrum of antibiotic activity and is much less active than erythromycins A and B.

ChEBI: Erythromycin C is an erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively. It is functionally related to an erythronolide A. It is a conjugate base of an erythromycin C(1+).